Canine Mast Cell Tumors: Grades, Treatment, Costs, and Clinical Trials in 2026
By Brycen Levings | Editor: Tariq Shah · July 8, 2026
The Most Common Skin Cancer in Dogs — and the Most Unpredictable
Mast cell tumors are the most common skin cancer in dogs, and one of the most unpredictable cancers in all of veterinary medicine. Two tumors that look identical under a microscope can behave completely differently — one cured by a single surgery, the other spreading to the spleen and liver within months. That variability is exactly why grading, staging, and increasingly, clinical trials, matter so much. Pet Trial Finder currently tracks 10 across accredited U.S. veterinary teaching hospitals. This guide covers what mast cell tumors are, how they're graded, what standard treatment costs, and what's being studied right now.
What Is a Canine Mast Cell Tumor?
Mast cells are immune cells that live in the skin and other tissues and release histamine during allergic reactions. When they become cancerous, they form mast cell tumors (MCTs) — most often as a lump in or under the skin, though they can also affect internal organs. Because these tumors are full of histamine and other inflammatory chemicals, they can swell, redden, or ulcerate, and disturbing them can trigger allergic-type reactions.
The Forms of Mast Cell Tumor
Cutaneous mast cell tumor is the classic presentation — a mass in the skin, with behavior ranging from entirely benign to aggressive. Subcutaneous mast cell tumor sits under the skin rather than within it and, as a group, tends to behave more favorably. Visceral mast cell tumor involves internal organs such as the spleen, liver, or intestines, and represents the more advanced, systemic form. KIT-mutated mast cell tumor refers to the roughly one-quarter to one-third of intermediate- and high-grade tumors that carry a mutation in the KIT gene — a mutation that drives aggressive growth but also makes the tumor a target for specific drugs.
Grade Is the Whole Ballgame
Two grading systems are in use, and your oncologist may report both. The Patnaik system is three-tier (Grade I, II, or III — least to most aggressive). The Kiupel system is two-tier (low-grade or high-grade) and tends to be more consistent between pathologists. Most low-grade tumors are cured by complete surgical removal alone. High-grade tumors are effectively a different disease: metastasis rates run high and many dogs face progression within the first year, which is where systemic therapy and trials come in. A prognostic panel (Ki-67, c-KIT PCR, KIT immunohistochemistry) can refine the picture in borderline cases.
Standard Treatment and What It Costs
Surgery with wide margins is the foundation of treatment for most MCTs, running $800 to $3,000 depending on size, location, and reconstruction. Stelfonta (tigilanol tiglate) is a non-surgical option injected directly into eligible tumors at $1,500 to $3,500 — roughly 75% of tumors respond to one injection and about 87–90% to two, with most treated dogs tumor-free at one year. Radiation therapy ($4,000 to $8,000) is used for incompletely removed tumors or difficult locations. Chemotherapy such as vinblastine with prednisone, or lomustine ($2,500 to $5,000), addresses high-grade or metastatic disease. Tyrosine kinase inhibitors (Palladia/toceranib, masitinib) are oral, at-home drugs especially useful for KIT-mutated tumors, at an ongoing monthly cost. Supportive antihistamines and antacids to manage histamine release are inexpensive. Prognosis tracks grade closely: low-grade tumors removed with clean margins often mean a normal life expectancy, while high-grade disease is where outcomes vary most — and where new therapy is most needed.
Clinical Trials: What Is Being Studied
Anti-KIT monoclonal antibodies are engineered to target the KIT protein on mast cells while sparing healthy immune cells — an approach borrowed from human oncology and now in development in dogs. Checkpoint inhibitors (caninized anti-PD-1 antibodies, a class recently introduced to veterinary medicine) are being evaluated to unmask high-grade tumors to the immune system. Next-generation targeted drugs aim at resistant or KIT-mutated tumors. And improved local therapies — better intralesional agents and electrochemotherapy — seek to control tumors without extensive surgery.
Who Qualifies for a Mast Cell Tumor Trial?
Most trials want a confirmed diagnosis by cytology or biopsy, a known grade, and baseline bloodwork. Some target high-grade or KIT-mutated tumors specifically; others enroll dogs whose tumors can't be fully removed by surgery. Both treatment-naive dogs and those who've relapsed after surgery or chemotherapy are represented in current studies
How Trial Costs Compare to Standard Treatment
Fully funded trials typically cover the investigational drug, trial-specific staging, and specialist monitoring — a meaningful offset against the cost of surgery-plus-radiation or long-term targeted therapy. The tradeoff is more frequent visits to the research institution and the uncertainty inherent in investigational treatment. Pet Trial Finder checks your dog against all 10— plus the full database of 133 trials across 39 cancer types — in a single application. Results in hours, not weeks.